| Cat.No. | Name | Information |
|---|---|---|
| M5137 | BML-277 | BML-277 is a high efficient Chk2 inhibitors, IC50 is 15 nM. |
| M2325 | CHIR-124 | CHIR-124 is a novel and potent Chk1 inhibitor with IC50 of 0.3 nM. |
| M1764 | PF-477736 | PF-477736 is a selective checkpoint kinase 1 (Chk1) inhibitor with Ki values of 0.49 nM and 47 nM for CHK1 and CHK2 respectively. |
| M1665 | AZD7762 | AZD7762 is a potent ATP-competitive checkpoint kinase inhibitor with an IC50 of 5 and <10 nM for CHK1 and CHK2 respectively. |
| M21501 | Monalizumab | Monalizumab is a first-in-class immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A). Monalizumab can be used in the study of head and neck squamous cell carcinoma (HNSCC). |
| M13622 | Prexasertib | Prexasertib (LY2606368) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a Ki of 0.9 nM and an IC50 of <1 nM. |
| M13621 | GDC-0575 dihydrochloride | GDC-0575 dihydrochloride (ARRY-575 dihydrochloride) is an orally bioavailable CHK1 inhibitor, with an IC50 of 1.2 nM, and has antitumor activity. |
| M11418 | SAR-020106 | Sar-020106 is an ATP-competitive and selective CHK1 inhibitor with an IC50 of 13.3 nM. Sar-020106 has good selectivity to CHK2. Sar-020106 increased cell lethality of Gemcitabine and SN38 by 3.0 to 29 times in a p53-dependent manner in several colon cancer cell lines. Sar-020106 can enhance antitumor activity by selecting anticancer drugs. |
| M10476 | GDC-0575 (ARRY-575) | GDC-0575 (ARRY-575, RG7741) is a potent and selective oral inhibitor of cell cycle checkpoint kinase 1 (Chk1) with an IC50 of 1.2 nM. |
| M10129 | CCT245737 | CCT245737 is a potent, selective and orally active checkpoint kinase 1 (CHK1) inhibitor, with IC50 values of 1.3 nM, 2440 nM and 30 nM for CHK1, CHK2 and G2 check point abrogation, respectively. |
| M9208 | PD0166285 | PD0166285 is a potent Wee1 inhibitor and Chk1 inhibitor with IC50s of 24 nM and 72 nM, respectively. |
| M9042 | Prexasertib dihydrochloride | Prexasertib (LY2606368) is a substrate ATP competitively selective inhibitor of CHK1 and CHK2 with IC50 values of <1 nM and 8 nM against CHK1 and CHK2, respectively. |
| M6104 | Ipilimumab | Ipilimumab (MDX-010, BMS-734016) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor. MW : 148 kD. |
| M5156 | CCT241533 hydrochloride | CCT241533 hydrochloride is a potent serine/threonine checkpoint kinase (Chk2) inhibitor with IC50 of 3 nM. |
| M3686 | AZD7762 hydrochloride | AZD7762 hydrochloride is a potent ATP-competitive checkpoint kinase inhibitor with an IC50 of 5 and <10 nM for CHK1 and CHK2 respectively. |
| M2324 | Rabusertib (LY2603618) | Rabusertib (LY2603618) is an effective and selective Chk1 inhibitor with an IC50 of 7 nM. |
| M1996 | SCH 900776 | SCH 900776 (MK-8776) is a highly potent and functionally selective CHK1 inhibitor with IC50 of 3 nM. |
| M1676 | BIBR1532 | BIBR1532 is a potent and selective telomerase inhibitor with IC50 of 93 nM. |
| M53358 | CBP501 Affinity Peptide | CBP501 Affinity Peptide is a Chk kinase inhibitor that can abrogate G2 arrest induced by DNA-damaging agents. |
| M53357 | Chktide | Chktide is a substrate for CHK1 and CHK2. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
